<DOC>
	<DOC>NCT02207634</DOC>
	<brief_summary>This study evaluates change over time in neurocognitive testing in subjects receiving statin therapy in combination with evolocumab (AMG 145), compared with subjects receiving statin therapy in combination with placebo.</brief_summary>
	<brief_title>Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<criteria>Randomized into Study 20110118 (FOURIER) Current or known past diagnosis of dementia or mild cognitive impairment (MCI)</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>High cholesterol</keyword>
	<keyword>Treatment for high cholesterol</keyword>
	<keyword>Lowering cholesterol</keyword>
	<keyword>Lowering high cholesterol</keyword>
	<keyword>Hypercholesterolemia</keyword>
</DOC>